MAI Capital Management’s Mereo BioPharma MREO Stock Holding History

MAI Capital Management’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-309	Closed	-$102	–	3700
2026 Q1	$102	Hold	309	–	–	﹤0.01%	4755
2025 Q4	$129	Hold	309	–	–	﹤0.01%	4124
2025 Q3	$637	Hold	309	–	–	﹤0.01%	3577
2025 Q2	$838	Hold	309	–	–	﹤0.01%	3670
2025 Q1	$696	Hold	309	–	–	﹤0.01%	3195
2024 Q4	$1.08K	Buy	+309	New	+$1.21K	﹤0.01%	3176

Other funds holding MREO

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

MAI Capital Management's MREO Position: Q2 2026 in Review

MAI Capital Management sold out of Mereo BioPharma (MREO) in Q2 2026, closing a stake of 309 shares — an estimated $102 sold.

MAI Capital Management first reported a position in MREO in Q4 2024 and held it in 6 quarters. The position peaked at $1.08K in Q4 2024. 60 funds tracked by Wall St. Rank hold MREO as of Q2 2026.

MAI Capital Management reported no remaining Mereo BioPharma position as of Q2 2026 after selling out during the quarter.
MAI Capital Management sold 309 Mereo BioPharma shares in Q2 2026, an estimated $102.
MAI Capital Management first reported a position in Mereo BioPharma in Q4 2024 and held it in 6 quarters.
MAI Capital Management's Mereo BioPharma position peaked at $1.08K in Q4 2024.
60 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.